INVO Bioscience reports Q4 revenue $278,142, vs. $12,532 last year

Reports Q4 adjusted EBITDA ($2.23M) vs $1.05M last year. "2022 was another important year overall for INVO," commented Steve Shum, CEO of INVO. "Our initial three INVO centers made steady progress throughout their first full year of operation, reaching a combined total revenue of over $1.6M, setting the stage for our plans to build additional INVO Centers with Tampa targeted to open soon. We further evolved our commercial efforts to build the Company by adding an acquisition strategy that is expected to allow us to synergistically introduce INVOcell into existing IVF clinics and to add profitable revenue sources to our operations. Additionally, we have made significant progress with our 5-day label enhancement efforts with the FDA."